Semnur Pharmaceuticals, Inc.

Semnur Pharmaceuticals, Inc., trading under the ticker DECA, is a clinical-stage pharmaceutical company focused on non-opioid pain management therapies that reached public markets through a SPAC merger. The company filed a Form 10-Q with the SEC on May 15, 2023, accession number 0001575872-23-000755, reflecting its status as an operating post-merger public company in the healthcare and life sciences sector. The filing covers a quarterly reporting period following the completion of its de-SPAC transaction, with the company pursuing its pipeline of proprietary analgesic drug candidates. Visit SpacDesk and sign up for full data, filings history, and deal analytics on DECA and hundreds of other SPAC transactions.